MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Marker Therapeutics, Inc. (MRKR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (C-). The rating has held at C+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | B (3.5) | C (2.4) | C- (2.0) | C+ (2.6) | C+ (2.7) |
| 2026-11-06 | B- (3.0) | B (3.5) | C (2.4) | C (2.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-30 | B- (3.0) | B (3.4) | C (2.5) | C (2.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-23 | B- (3.0) | B (3.4) | C (2.4) | C (2.4) | C+ (2.6) | C+ (2.8) |
| 2026-10-16 | B- (3.0) | B (3.4) | C (2.4) | D+ (1.8) | C+ (2.6) | C+ (2.7) |